Abolishing the prelamin A ZMPST24 cleavage site leads to progeroid phenotypes with near-normal longevity in mice

Yuexia Wang, Khurts Shiligardi, Trunee Hsu, Kansi O. Odinammadu, Takamitsu Maruyama, Wei Wu, Chuyan-Sheng Lin, Christopher B. Damoci, Eric D. Spear, Ji-Yeon Shin, Wei Hsu, Susan Michaelis, and Howard J. Worms

*Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032; †Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032; ‡Department of Cell Biology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; §Department of Biology, Case Western Reserve University, Cleveland, OH 44106; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642; ††Department of Dentistry, University of Rochester Medical Center, Rochester, NY 14642; and ‡‡Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032

Edited by Ying-Hui Fu, Department of Neurology, University of California, San Francisco, CA; received October 12, 2021; accepted January 10, 2022

Prelamin A is a farnesylated precursor of lamin A, a nuclear lamina protein. Accumulation of the farnesylated prelamin A variant progerin, with an internal deletion including its processing site, causes Hutchinson–Gilford progeria syndrome. Loss-of-function mutations in ZMPST24, which encodes the prelamin A processing enzyme, lead to accumulation of full-length farnesylated prelamin A and cause related progeroid disorders. Some data suggest that prelamin A also accumulates with physiological aging. Zmpst24−/− mice die young, at ~20 wk. Because ZMPST24 has functions in addition to prelamin A processing, we generated a mouse model to examine effects solely due to the presence of permanently farnesylated prelamin A. These mice have an L648R amino acid substitution in prelamin A that blocks ZMPST24-catalyzed processing to lamin A. The LmnaL648R/L648R mice express only prelamin A and no mature protein. Notably, nearly all survive to 65 to 70 wk, with ~40% of male and 75% of female LmnaL648R/L648R mice having near-normal lifespans of 90 wk (almost 2 y). Starting at ~10 wk of age, LmnaL648R/L648R mice of both sexes have lower body masses than controls. By ~20 to 30 wk of age, they exhibit detectable cranial, mandibular, and dental defects similar to those observed in Zmpst24−/− mice and have decreased vertebral bone density compared to age- and sex-matched controls. Cultured embryonic fibroblasts from LmnaL648R/L648R mice have aberrant nuclear morphology that is reversible by treatment with a protein farnesyltransferase inhibitor. These novel mice provide a model to study the effects of farnesylated prelamin A during physiological aging.

Significance

The zinc metalloprotease ZMPST24 removes the last 15 amino acids of prelamin A, including a farnesylated cysteine, to produce mature lamin A. The premature aging disorder Hutchinson–Gilford progeria syndrome is caused by a permanently farnesylated prelamin A variant lacking the ZMPST24 cleavage site. ZMPST24 loss of function leads to the accumulation of farnesylated prelamin A and causes progeroid disorders. Some studies have implicated prelamin A in physiological aging. We describe mice with an amino acid substitution in prelamin A that blocks the ZMPST24-catalyzed cleavage. These mice develop progeroid phenotypes but, in contrast to those modeling Hutchinson–Gilford progeria syndrome or ZMPST24 deficiency, have near-normal lifespans, thus providing a model to study the effects of farnesylated prelamin A during aging.
potential to illuminate the role of permanently farnesylated prelamin A in physiologic aging. Zmpste24/C0/C0 mice accumulate farnesylated prelamin A and develop progeroid phenotypes, including severe growth retardation, craniofacial abnormalities, spontaneous bone fractures, and have a median survival of only \(\sim 20\) wk (9, 10). In Zmpste24/C0/C0 mice, disease severity is ameliorated by genetic reduction of prelamin A or pharmacological treatment to block protein farnesylation (11–13). These findings, along with those showing a correlation between disease severity and residual enzyme activity in humans with ZMPSTE24 mutations, suggest a “dose–response” between the amount of farnesylated prelamin A and the degree of pathology. However, ZMPSTE24 has at least one other function besides prelamin A processing, namely clearing clogged translocons (14, 15). Hence, some of the organismal pathology caused by ZMPSTE24 deficiency may result from defects in protein translocation into the endoplasmic reticulum (ER). ZMPSTE24 may also have additional functions, inferred from its contribution to viral defense in mice (16, 17) and from genetic studies in yeast that have implicated it in ER protein quality control, membrane stress, and establishing membrane protein topology (18–22).

Substitution of a hydrophobic residue with an arginine at the ZMPSTE24 cleavage site in prelamin A (V637R in chickens and L647R in humans) blocks its proteolysis (23, 24), resulting in the accumulation of permanently farnesylated prelamin A. We have previously reported a patient with a heterozygous LMNA mutation generating the L647R amino acid substitution in prelamin A. This patient had a relatively mild progeroid disorder with clinical features similar to those of MAD-B (25). We therefore generated and characterized mice with the corresponding L648R amino acid substitution in prelamin A to determine if \(Lmna^{L648R/L648R}\) mice have the same or different phenotype and disease severity as \(Zmpste24^{+/+}\) mice.

**Results**

**Generation and Survival of \(Lmna^{L648R}\) Mice.** Normally, farnesylated prelamin A is a transient species, essentially undetectable in cells because of its efficient conversion to mature lamin A. However, LMNA mutations causing HGPS, ZMPSTE24 mutations causing RD and MAD-B, and the LMNA L647R mutation causing a MAD-B–like disorder, lead to accumulation of farnesylated prelamin A or variants (Fig. 1). Whereas several

---

**Fig. 1.** Survival of mice with a \(Lmna^{L648R}\) mutation corresponding to the human mutation LMNA L647R that encodes an uncleavable variant of prelamin A. (A) Prelamin A is normally processed to lamin A after proteolytic cleavage catalyzed by the zinc metalloprotease ZMPSTE24 between tyrosine (Y) and leucine (L) 647 (648 in mouse), removing a peptide containing the carboxyl-terminal farnesylated cysteine (C). HGPS-causing LMNA mutations generate a prelamin A variant with an internal deletion of 50 amino acids (Δ50) called progerin, which lacks the ZMPSTE24 cleavage site and retains a farnesylated carboxyl-terminal cysteine. ZMPSTE24 loss-of-function mutations cause RD or MAD-B, in which unprocessed farnesylated prelamin A accumulates. LMNA mutation causing a MAD-B–like disorder generates a leucine (L) to arginine (R) substitution at residue 647 of prelamin A blocks ZMPSTE24 processing, leading to expression of a farnesylated variant with only a single amino acid difference. (B) Immunoblots of protein extracts from livers of \(Lmna^{+/+}\), \(Lmna^{−/−}\), \(Lmna^{−/−}L648R\), and \(Lmna^{−/−}L648R\) mice. Blots were probed with an antibody specific for prelamin A (Top), an anti-lamin A/C antibody that recognized prelamin A, lamin A, and lamin C (Middle), or anti-GAPDH antibody as loading control (Bottom). (C) Survival curves for male \(L648R/L648R\) (\(n = 19\)), +/+L648R (\(n = 17\)), and +/+ (\(n = 10\)) mice and female \(L648R/L648R\) (\(n = 11\)), +/+L648R (\(n = 15\)), and +/+ (\(n = 8\)) mice.
mouse lines with HGPS-causing and Zmpste24 loss-of-function mutations have been generated and characterized (9, 10, 26–31), a mouse with a single amino acid substitution in prelamin A that causes a MAD-B–like disease in humans does not exist. Such a mouse could provide valuable information on the impact of prelamin A on promoting aging phenotypes, absent the complications in Zmpste24/C0 mice, where altered processing of substrates in addition to prelamin A or other disrupted pathways may contribute to the phenotypes.

We therefore used a recombination-mediated genetic engineering strategy to generate mice carrying a LmnaL648R allele (SI Appendix, Fig. S1A). It should be noted that L648R in mice is equivalent to L647R in humans. Founder mice carried one mutant and one wild-type allele (SI Appendix, Fig. S1B). We crossed founder male mice to female Lmna+/+ C57BL/6J mice and intercrossed the heterozygous male and female L648R/+ and L648R/L648R mice at the indicated ages. (B) Body fat volume (Left) and body fat volume normalized to body mass (Right) of 52-wk-old male and female +/- and L648R/L648R mice. Each triangle or circle represents value for an individual animal; long horizontal bars represent mean and errors bars indicate SEM.

As expected, LmnaL648R/+ mice expressed mature lamin A and lamin C, LmnaL648R/L648R mice expressed prelamin A, lamin A, and lamin C, and LmnaL648R/L648R mice expressed prelamin A and lamin C, at roughly the same levels, but no mature lamin A (Fig. 1B and SI Appendix, Fig. S1C). For analysis of survival and growth, as well as all subsequent experiments, we used mice that were crossed several generations onto a >90% pure C57BL/6J background. The homozygous LmnaL648R/L648R mice

**Fig. 2.** Growth of LmnaL648R/L648R mice. (A) Body mass versus age of male LmnaL648R/L648R (+/L648R) (n = 20), Lmna+/L648R (n = 12), and Lmna+/+ (n = 13) mice and female L648R/L648R (n = 13), +/L648R (n = 15), and +/- (n = 11) mice. Values are means and error bars indicate SEM. (B) Photographs comparing the sizes of male and female +/- and L648R/L648R mice at the indicated ages. (C) Body fat volume (Left) and body fat volume normalized to body mass (Right) of 52-wk-old male and female +/- and L648R/L648R mice. Each triangle or circle represents value for an individual animal; long horizontal bars represent mean and errors bars indicate SEM.
had unexpectedly long lifespans, with nearly all living 65 to 70 wk and ∼40% of male and ∼75% of female Lmna<sup>L648R/L648R</sup> alive at 90 wk (almost 2 y) of age (Fig. 1C).

**Growth and Metabolic Features of Lmna L648R Mice.** Heterozygous and homozygous Lmna<sup>L648R</sup> mice were grossly indistinguishable from their wild-type littermates early in life. Starting at ∼10 wk of age, however, Lmna<sup>L648R/L648R</sup> mice had decreased body masses and this difference became accentuated over time (Fig. 2A). Given the normal growth and survival of heterozygous Lmna<sup>+/L648R</sup> mice, we performed more detailed phenotypic analyses only on the homozygous Lmna<sup>L648R/L648R</sup> mice compared to Lmna<sup>+/+</sup> wild-type mice. Similarly, many other heterozygous Lmna mutant mice, including some heterozygous for the HGPS mutation, have modest, minimal, or in many cases no abnormal phenotypes (32, 33). Consistent with their decreased body mass compared to wild-type mice with aging, male and female Lmna<sup>L648R/L648R</sup> mice were visibly smaller than Lmna<sup>+/+</sup> animals of the same age at 56 and 74 wk (Fig. 2B).

Zmpste24<sup>−/−</sup> mice have severe lipodystrophy along with growth retardation (9, 10). We therefore examined body fat composition and various metabolic parameters in Lmna<sup>L648R</sup> mice. Male and female Lmna<sup>L648R/L648R</sup> mice both had significantly reduced body fat at 52 wk of age, compared to wild-type mice (Fig. 2C). However, fasting blood glucose concentration at 30 wk was not significantly different between Lmna<sup>L648R/L648R</sup> and wild-type mice (SI Appendix, Fig. S2A). Likewise, glucose tolerance testing showed no difference between male Lmna<sup>L648R/L648R</sup> and Lmna<sup>+/+</sup> mice, but the female mutant mice had decreased glucose tolerance compared to wild-type controls (SI Appendix, Fig. S2B). Female Lmna<sup>L648R/L648R</sup> also had lower plasma insulin concentrations compared to sex-matched Lmna<sup>+/+</sup> mice (SI Appendix, Fig. S2C). There were no significant differences in other routine blood biochemical parameters between Lmna<sup>L648R/L648R</sup> and Lmna<sup>+/+</sup> mice (SI Appendix, Table S1). Thus, while Lmna<sup>L648R/L648R</sup> mice clearly have low body mass and body fat, these phenotypes are not associated with any major prominent serum metabolic abnormality, except possible mild insulin resistance in female mice.

**Cranial and Mandibular Defects in Lmna<sup>L648R/L648R</sup> Mice.** Zmpste24<sup>−/−</sup> mice have profound cranial and mandibular abnormalities of the zygomatic arch, mandible, and dentition (9, 10). The human patient with the LMNA L647R mutation has microcephaly, micrognathia, and dental crowding (25). We therefore examined the skulls of Lmna<sup>L648R/L648R</sup> mice by microcomputed tomography (micro-CT). At 4 wk of age, skulls of male and female Lmna<sup>L648R/L648R</sup> mice were essentially indistinguishable from Lmna<sup>+/+</sup> mice. The zygomatic arches developed normally with the proper formation of both zygomaticotemporal and zygomaticomaxillary sutures in Lmna<sup>L648R/L648R</sup> mice (Fig. 3A).

When rescaned at 30 wk of age, however, male and female Lmna<sup>L648R/L648R</sup> mice exhibited wide-open zygomaticotemporal sutures in one or both zygomatic arches (Fig. 3B). These defects were present in one or both zygomatic arches in the majority of male and female Lmna<sup>L648R/L648R</sup> mice but not in any Lmna<sup>+/+</sup> mice at 30 wk of age (Fig. 3C). The normal zygomatic arches 4 wk after birth and defects at older ages implies that these are degenerative but not developmental deformities.

By 20 wk of age, and more prominently at 30 wk of age, micro-CT imaging and three-dimensional (3D)-reconstruction analyses revealed profound mandibular degeneration in male and female Lmna<sup>L648R/L648R</sup> mice (SI Appendix, Fig. S3). The 3D rendering of micro-CT-scanned skull images after segmentation of mandible further examined the degenerative defects. The condylar, coronoid, and angular processes were severely deformed, resulting in decreased mandibular length, mandibular body length, and ramus height. (Fig. 4A). Mandible dimensions were significantly decreased in both male and female Lmna<sup>L648R/L648R</sup> mice compared to age- and sex-matched Lmna<sup>+/+</sup> controls (Fig. 4B). Dental malocclusion occurs in mice when the incisors overgrow because the mandibular and maxillary teeth are not normally aligned. Although oral examination showed the male and female Lmna<sup>L648R/L648R</sup> had minimal to mild dental malocclusion at 30 wk of age, this condition was quite evident at ages older than 70 wk (Fig. 4C).

This was confirmed by micro-CT scanning (SI Appendix, Fig. S4). By 65 wk of age, virtually all male and 85% of female Lmna<sup>L648R/L648R</sup> mice had dental malocclusion (Fig. 4D). This was likely attributed to the mandibular degeneration, leading to the improper alignment of the upper and lower jaws. Lmna<sup>L648R/L648R</sup> mice clearly have mandibular and dental defects, which could compromise dietary intake and may

![Fig. 3. Degenerative deformities in zygomatic arches of Lmna<sup>L648R/L648R</sup> mice.](image-url)

(A) Representative 3D renderings of the micro-CT images of male and female Lmna<sup>L648R/L648R</sup> and Lmna<sup>+/+</sup> mice showing the formation of the zygomatic arches (green arrows) at 4 wk. (B) Degenerative deformity (red arrows) in the zygomaticotemporal suture of male and female Lmna<sup>L648R/L648R</sup> mice compared to the proper maintenance (green arrows) in the +/- mice at 30 wk. (C) Percentages of male +/- (n = 7), female +/- (n = 7), male Lmna<sup>L648R/L648R</sup> (n = 10), and female Lmna<sup>L648R/L648R</sup> (n = 9) mice with degenerative deformity in 0, 1, or 2 zygomatic arches of 30 wk of age.

![Fig. 4. Mandible dimensions.](image-url)

(Male) and (Female)
Malocclusion

body length; ML: mandibular length; RH: ramus height. (female and male between female Mandibular defects in older ages. (both male and female obtain bone and nonbone volumes (Fig. 5 image and computed statistical information of the 3D model to the trabecular bone area. Next, we generated the 3D-rendered (2D) images, we first segmented the vertebra L5 by selecting Lmna reduced vertebral bone density compared to sex-matched surface than those of SI Appendix mutations but appear less severe and are not prominent until Lmna CT–scanned images to analyze vertebral bone density in and bone fractures (9, 10, 12, 34). We therefore used micro-

A

B

C

D

Fig. 4. Mandibular defects in LmnaL648R/L648R mice. (A) Representative 3D renderings of the segmented micro-CT–scanned images showing mandibles of male and female LmmaL648R (+/+) and LmnaL648R/L648R (L648R/L648R) mice. A: angular process; Cr: condylar process; Cr: coronoid process; MBL: mandibular body length; ML: mandibular length; RH: ramus height. (8) Comparisons of ML, MBL, and RH between male +/+ (n = 4) and L648R/L648R (n = 4) mice and between female +/+ (n = 4) and L648R/L648R (n = 4) mice. Values are means and error bars indicate SEM. (C) Representative photographs of teeth of male and female +/+ and L648R/L648R mice at the ages in weeks indicated. Dental malocclusion is minimal to mild at 30 wk of age and more severe at older ages. (D) Percentages of male +/+ (n = 13), female +/+ (n = 10), male L648R/L648R (n = 18) and female L648R/L648R (n = 13) mice with malocclusion at ≥65 wk of age.

contribute to decreased body mass observed with advancing age. The mandibular and dental abnormalities in LmnaL648R/L648R mice resemble those of Zmpste24−/− mice and those with HGPS mutations but appear less severe and are not prominent until later in life.

Decreased Vertebral Bone Density and Long Bone Defects in LmnaL648R/L648R Mice. Zmpste24−/− mice suffer from osteoporosis and bone fractures (9, 10, 12, 34). We therefore used micro-

we also examined grip strength and ribs of LmnaL648R/L648R mice. At 35 wk of age, there was no difference in grip strength between LmnaL648R/L648R and Lmna+/+ mice of both male and female sex (SI Appendix, Fig. S5A). Even in three female LmnaL648R/L648R mice that survived to 104 to 120 wk of age, grip strength was no different from age-matched controls (SI Appendix, Fig. S5B). We used micro-CT to examine the middle thoracic spines and ribs of dissected and fixed skeletons from five male and six female LmnaL648R/L648R mice killed at 30 wk of age and did not observe any rib fractures (SI Appendix, Fig. S5C). Micro-CT of seven male and five female live LmnaL648R/L648R mice at 52 wk of age also did not detect rib fractures. Micro-CT scans of dissected and fixed skeletons from three male and one female LmnaL648R/L648R mouse that died or had to be killed at 76 to 84 wk of age identified two broken ribs in the vicinity of the costovertebral junction with hypertrophic calluses at the fracture sites in one mouse (SI Appendix, Fig. S5D). In contrast to Zmpste24−/− mice, which have grip abnormalities and nearly every rib broken by 24 to 30 wk of age (9), LmnaL648R/L648R mice have preserved grip strength throughout their lifetimes and only rare rib fractures at old, preterminal ages.

Farnesylation-Dependent Abnormal Nuclear Morphology in LmnaL648R/L648R Mouse Embryonic Fibroblasts. We isolated fibroblasts from LmnaL648R/L648R and Lmna+/+ mouse embryos. Immunoblotting confirmed that LmnaL648R/L648R MEFs produce only prelamin A and no mature lamin A, whereas the reverse is the case for Lmna+/+ mouse embryonic fibroblasts (MEFs). (Fig. 6A). Immunostaining similarly reveals that prelamin A accumulates in LmnaL648R/L648R MEFs but not in Lmna+/+ MEFs (Fig. 6B). A high percentage of misshapen nuclei are apparent in mutant cells and this trend is amplified with passage number (Fig. 6C). Treatment of LmnaL648R/L648R

Wang et al. Abolishing the prelamin A ZMPSTE24 cleavage site leads to progeroid phenotypes with near-normal longevity in mice

https://doi.org/10.1073/pnas.2118695119

PNAS | 5 of 10
MEFs with the protein farnesyltransferase inhibitor (FTI) lona-farnib corrected the abnormal nuclear morphology (Fig. 6D). The percentage of mutant MEFs with abnormal nuclear morphology was significantly less in cultures treated with FTI compared to vehicle only (Fig. 6E). These results strongly suggest that accumulation of the farnesylated form of prelamin A is responsible for abnormal nuclear morphology. Given the correlations between FTI-induced reversal of abnormal nuclear morphology in MEFs from Zmpste24−/− and HGPS mutant mice and the beneficial effects of these drugs on the corresponding whole animals (11, 31, 35–37), the farnesylated form of prelamin A variant (and no mature lamin A) with a single amino acid substitution at the ZMPSTE24 cleavage site that prevents farnesylation may be less “toxic” to cells than prelamin A, which contains the farnesyl and carboxylmethyl moieties of prelamin A that are more difficult to reconcile with the wealth of data suggesting that it is far less than native prelamin A, and determining whether binding of this variant to the known prelamin A interactors, such as AKT and SUN1 (44–46), is diminished would be of interest to test in the future. However, this explanation is difficult to reconcile with the wealth of data suggesting that it is the farnesyl and carboxymethyl moieties of prelamin A that are essential for its adverse effects in cultured cells and mice (45–47). Furthermore, mice engineered to express only a nonfarnesylated prelamin A, without any lamin C, develop cardiomyopathy but do not have progeroid phenotypes and live much longer and have less severe growth retardation than Zmpste24−/− mice (38).

Discussion

HGPS, MAD-B, and other progeroid disorders arise from genetic mutations that lead to the accumulation of permanently farnesylated prelamin A or variant proteins (1–5). We have generated Lmna<sup>L648R/L648R</sup> mice that accumulate a farnesylated prelamin A variant (and no mature lamin A) with a single amino acid substitution at the ZMPSTE24 cleavage site that blocks processing. Like mice with Lmna mutations that lead to production of progerin and Zmpste24−/− mice that accumulate prelamin A, the Lmna<sup>L648R/L648R</sup> mice develop progeroid phenotypes. Fibroblasts from these mice also have abnormal nuclear morphology that is reversible by pharmacological blockade of protein farnesylation, which is also the case for human and mouse cells expressing progerin or deficient in ZMPSTE24 (38). Notably, however, Lmna<sup>L648R/L648R</sup> mice have dramatically greater longevity (~1.5 to >2 y) as compared to Zmpste24−/− mice (4 to 7 mo) (9, 10) and Lmna mouse models of HGPS that have two mutant alleles encoding progerin (4 to 10 mo) (26, 27, 29, 39). Because Lmna<sup>L648R/L648R</sup> mice do not die prematurely, and can live more than 2 y, they are an ideal model for studying the effects of permanently farnesylated prelamin A in the context of physiologic aging.

The phenotype of Lmna<sup>L648R/L648R</sup> mice in some ways resembles that of the one human patient described to date with the clinical and histological features of HGPS, Lmna<sup>L647R</sup> mutation (25). The patient was small for chronologic age, microcephalic, and had a “MAD-B-like” condition with micrognathia, dental crowding, decreased subcutaneous fat and bone defects, including acne-osteolysis and other radiological findings suggestive of abnormal bone resorption or deposition. Fibroblasts from this patient expressed prelamin A to lamin A at a ratio of ~1:1; however, this individual was not nearly as severely affected as children with HGPS that are heterozygous for the LMNA G608G allele and whose fibroblasts generally express progerin to lamin A at a <1:1 ratio. Although the human data are from only one individual, they suggest that full-length prelamin A may be less “toxic” to cells than progerin, which contains a 50-amino acid deletion.

To a large extent, Lmna<sup>L648R/L648R</sup> mice phenocopy what has been reported for Zmpste24−/− mice in terms of growth, skull, and other bone defects (9, 10, 12, 34). However, their phenotype is far less severe than that of Zmpste24−/− mice and they do not exhibit premature lethality. Both mice have severe mandibular and dental abnormalities that could potentially lead to malnourishment, causing the observed failure to thrive. However, Lmna<sup>L648R/L648R</sup> mice have decreased body mass compared to wild-type mice at ages before dental malocclusion becomes prominent, suggesting that factors other than dental abnormalities resulting in decreased caloric intake may contribute to their failure to thrive. Lmna<sup>L648R/L648R</sup> mice also have decreased whole body fat content, as do Zmpste24−/− mice and humans with MAD-B (7, 9, 10, 40, 41). Decreased body fat content of Lmna<sup>L648R/L648R</sup> mice was not associated with insulin resistance. Female Lmna<sup>L648R/L648R</sup> mice had modest hyperglycemia after glucose administration, but a lower-than-normal plasma insulin concentration. Zmpste24−/− mice also have plasma insulin concentrations lower than wild-type mice (42). Conditional deletion of Zmpste24 from adipocytes leads to only modest body fat loss only in male mice (43). These findings suggest that decreased body fat in Lmna<sup>L648R/L648R</sup> mice is not caused by a direct effect of prelamin A on adipocytes.

Why are Lmna<sup>L648R/L648R</sup> mice similar to, but less severely affected than Zmpste24−/− mice, given that both express solely farnesylated prelamin A and no mature lamin A? One possibility is that they are exposed to a lower “dose” of prelamin A. Zmpste24−/− mice are heterozygous for an Lmna knockout allele, which express half the amount of prelamin A, have significantly less severe phenotypes than Zmpste24−/− mice with two wild-type Lmna alleles (12, 13). However, Lmna<sup>L648R/L648R</sup> mice like Zmpste24−/− mice with two wild-type Lmna alleles express roughly equal amounts of prelamin A relative to lamin C, so this explanation seems unlikely (12, 13). Another possibility is that the single amino acid substitution renders the L648R variant less “toxic” than native prelamin A, and determining whether binding of this variant to the known prelamin A interactors, such as AKT and SUN1 (44–46), is diminished would be of interest to test in the future. However, this explanation is difficult to reconcile with the wealth of data suggesting that it is the farnesyl and carboxymethyl moieties of prelamin A that are primarily responsible for its adverse effects in cultured cells and mice (45–47). Furthermore, mice engineered to express only a nonfarnesylated prelamin A, without any lamin C, develop cardiomyopathy but do not have progeroid phenotypes and live much longer and have less severe growth retardation than Zmpste24−/− mice (38).
We favor the hypothesis that ZMPSTE24’s other crucial cellular functions, in addition to prelamin A cleavage, contribute to the severity of phenotypes and limited lifespan of the Zmpste24−/− mice. ZMPSTE24 has a key role in clearing clogged translocons, as well as other less mechanistically well-understood roles in viral defense, protein secretion, ER protein quality control, membrane stress, and establishing membrane protein topology (14–22). While genetic reduction of prelamin A clearly improves the abnormal phenotypes of Lmna−/− mice (12, 48), in any case, much research has focused on progerin may make it more toxic than full-length prelamin A. Hence, the loss of 50 amino acids in Lmna−/− mice makes them more susceptible to a “toxic dose” of prelamin A or create additional pathologies that exacerbate those resulting from this dose. LmnaL648R/L648R mice also live significantly longer and have milder phenotypes than reported for various mouse models expressing progerin, the prelamin A variant in HGPS (26–29, 31, 37). Indeed, Ragnauth et al. (57) have reported that prelamin A accumulation is prevalent in the medial vascular smooth-muscle cells, adventitial thickening, and other pathological alterations that lead to sclerotic plaques in coronary arteries (52–55). This vascular pathology is the cause of myocardial infarctions and ischemic heart disease invariably present in individuals with HGPS.

Several mouse models of HGPS develop vascular alterations that mimic this human pathology (26–30, 56). Zmpste24−/− mice may die at too young an age to determine if prelamin A accumulation causes vascular pathology. LmnaL648R/L648R mice therefore provide a model to determine the effects of prelamin A in the development of cardiovascular disease. We did not observe vascular pathology when we examined these mice at 7 mo of age; however, we will continue to monitor them to see if it develops with advancing age or in combination with genetic susceptibility to atherosclerosis, as has been done with HGPS model mice (56).

Brayson et al. (49) reported that transgenic cardiomyocyte-specific expression of human prelamin A with the L647R amino acid substitution causes cardiomyopathy in mice, with abnormal heart function detected as early as 4 wk of age. In contrast, our mice expressing the mouse prelamin A L648R variant from the endogenous Lmna alleles lived almost 2 y without evidence of cardiomyopathy. Although only a few MAD-B patients have been thoroughly described in the literature (7), early-onset primary cardiomyopathy has not been described as a feature of these individuals. One patient with MAD-B and a compound heterozygous ZMPSTE24 mutation reportedly has a greater carotid intima media thickness relative to chronological age, and a raised proteomic classifier for the diagnosis of coronary artery disease (50). Cardiac complications of cardiovascular disease, rather than primary cardiomyopathy, lead to early death in HGPS (51). Arteries from patients with HGPS show loss of medial smooth-muscle cells, adventitial thickening, and other pathological alterations that lead to sclerotic plaques in coronary arteries (52–55). This vascular pathology is the cause of myocardial infarctions and ischemic heart disease invariably present in individuals with HGPS.

We favor the hypothesis that ZMPSTE24’s other crucial cellular functions, in addition to prelamin A cleavage, contribute to the severity of phenotypes and limited lifespan of the Zmpste24−/− mice. ZMPSTE24 has a key role in clearing clogged translocons, as well as other less mechanistically well-understood roles in viral defense, protein secretion, ER protein quality control, membrane stress, and establishing membrane protein topology (14–22). While genetic reduction of prelamin A clearly improves the abnormal phenotypes of Lmna−/− mice (12, 48), in any case, much research has focused on progerin may make it more toxic than full-length prelamin A. Hence, the loss of 50 amino acids in Lmna−/− mice makes them more susceptible to a “toxic dose” of prelamin A or create additional pathologies that exacerbate those resulting from this dose. LmnaL648R/L648R mice also live significantly longer and have milder phenotypes than reported for various mouse models expressing progerin, the prelamin A variant in HGPS (26–29, 31, 37). Indeed, Ragnauth et al. (57) have reported that prelamin A accumulation is prevalent in the medial vascular smooth-muscle cells, adventitial thickening, and other pathological alterations that lead to sclerotic plaques in coronary arteries (52–55). This vascular pathology is the cause of myocardial infarctions and ischemic heart disease invariably present in individuals with HGPS.

Several mouse models of HGPS develop vascular alterations that mimic this human pathology (26–30, 56). Zmpste24−/− mice may die at too young an age to determine if prelamin A accumulation causes vascular pathology. LmnaL648R/L648R mice therefore provide a model to determine the effects of prelamin A in the development of cardiovascular disease. We did not observe vascular pathology when we examined these mice at 7 mo of age; however, we will continue to monitor them to see if it develops with advancing age or in combination with genetic susceptibility to atherosclerosis, as has been done with HGPS model mice (56). Indeed, Ragnauth et al. (57) have reported that prelamin A accumulation is prevalent in the medial vascular smooth muscle cells of human arteries from old individuals, but not young ones, and in atherosclerotic lesions. This prelamin A accumulation is associated with reduced ZMPSTE24, suggesting that loss of its activity may change with aging. This
same group also reported that prelamin A was present in vascular smooth muscle cells in calcified arteries of subjects receiving renal dialysis, a model for vascular aging (58). This raises the possibility that prelamin A accumulation contributes to pathology associated with physiological aging. Because of the near-normal lifespan of the Lmna<sup>L648R/L648R</sup> mice, they will provide a model to determine the impact of prelamin A on the vasculature during aging.

**Materials and Methods**

**Mice.** The Institutional Animal Care and Use committee at Columbia University Irving Medical Center approved all protocols. We used recombination-mediated genetic engineering or recombining to construct vectors for manipulation of the mouse genome (59). Bacterial artificial chromosome clone RP23-281P8 carrying Lmna was purchased from BACPAC Resource. We engineered the T > G transversion at Lmna c.2176 in exon 11, which changed codon 648 CTC encoding Leu to GCC encoding Arg. We then inserted a Frt-Neo-Frt (FNF) cassette into intron 11 (S1 Appendix, Fig. S1A). A targeting vector was constructed by deleting the 1.6-kb left homology arm (5’ to L648R mutation), the FNF cassette, and the 1.45-kb right homology arm (end of FNF cassette to 3’) into pMCS-DTA vector carrying the Diphtheria toxin α-chain (DTA)-negative selection marker. The FNF cassette was then removed by crossing mice with the Lmna-L648R-FNF allele. The FNF cassette was then removed by crossing mice with the Lmna-L648R-FNF allele to B6.Cg-Tg(ActFLPeR)920DSym/J mice (The Jackson Laboratory; stock no: 005703). The offspring were crossed to wild-type C57BL/6J mice and heterozygous offspring subsequently crossed to wild-type C57BL/6J mice (The Jackson Laboratory; stock no: 005703). The offspring were crossed to wild-type C57BL/6J mice and heterozygous offspring subsequently crossed to wild type C57BL6J mice for another several generations before intercrossing the mice used in the experiments on a near-normal background.

**Micro-CT and Image Analysis.** Mice and dissected bones were scanned using the Perkin-Elmer Quantum FX micro-CT imaging system (PerkinElmer) at the Columbia mice X-ray Microscopy and Image Core at Columbia University Irving Medical Center. For imaging mice, the animal was anesthetized with 2% to 3% isoflurane. The skeletal structure of the mouse was scanned in the axial plane placed in a cylindrical sample holder at the field of view of 20 to 60 mm for lower-high resolution. A single scan of 4 min was taken, and the animal then was removed from the micro-CT machine, returned to its cage, and kept warm for homeothermic stability until consciousness returned. Dissected bones were placed on the sample holder and scanned at the same settings as for mice. Micro-CT VOX files were analyzed using Analyze 14.0 (AnalyzeDirect) and images were created using a surface rendering technique. The VOX files were also transferred to DICOM format and analyzed using AMIRA software. To obtain high-resolution images (6.6 µm), the dissected heads were scanned by SkyScan 1272 (Bruker BioSpin). For mandible size analysis, the scanned 2D images were segmented to select the mandibular area, followed by rendering of a 3D model from the segmented images, and computed statistical information of the 3D model analyzed to obtain the structure measurements using AMIRA software (Thermo Fisher Scientific). For bone density analysis, the top 60 images of vertebra L5 were segmented by selecting the trabecular bone area in all 20 images, and then the 60 segmented images were used to construct a 3D surface model. The computed statistical information of the 3D model was used to obtain bone volume and nonbone volume, followed by statistical analysis.

**Grip Strength Measurements.** For grip strength measurement, mice were placed in front of a Chati- lon digital force gauge pull meter (Columbus Instruments) with angled mesh assembly and allowed to grasp the pull bar with forelimbs and then paused backward by the tail until the grip was broken. Force applied to the bar the moment the grip was released was recorded. Each mouse pulled the grid three times in a row and then returned in the cage for a rest period of at least 1 min. This was repeated five times for a total of 15 pulls. Maximum grip strength was determined by averaging the three highest pull measurements of the 15 values, and normalized to body mass.

**MEF Isolation, Culture, Immunoblotting, Immunofluorescence Microscopy, and FTI Treatment.** Fibroblasts were isolated from 13.5-d embryos of female Lmna<sup>L648R/L648R</sup> mice that were crossed with male Lmna<sup>L648R/L648R</sup> mice using previously described methods (63). Primary MEFs were cultured in Dulbecco’s modified Eagle medium (Invitrogen or Thermo Fisher Scientific) containing 10% fetal bovine serum (FBS; Gemini) with 5% CO<sub>2</sub> at 37 °C and propagated in the same media containing penicillin-streptomycin-glutamine (1:100 dilution of Bio-Rad) and antibiotics (5 µg/mL streptomycin, 5 µg/mL amphotericin B, and 100 IU/mL penicillin) for at least 1 week. MEFs were dissociated using trypsinization and plated into a 10-cm dish in DMEM. MEFs at the indicated passages were grown in a barrier facility with 12/12-h light/dark cycles, fed a chow diet, and genotyped by PCR using genomic DNA isolated from tail clippings.

**Immunoblotting of Proteins Isolated from Mouse Tissues.** Proteins were extracted from mouse tissues, separated by electrophoresis in SDS-polyacrylamide slab gels, transferred to nitrocellulose membranes, and analyzed by immunoblotting using methods described previously (60). Primary antibodies for immunoblotting were rabbit anti-lamin A/C (Santa Cruz) at 1:5,000 dilution, rat monoclonal anti-prenylated A 3C8 (61) (kindly provided by the Progeria Research Foundation) dissolved in dimethyl sulfoxide (DMSO), and anti-mouse (LI-COR) and Alexa Fluor 647 donkey anti-rat (Abcam) secondary antibodies. For quantification, films were scanned with a digital camera and the band signal intensities were quantified using Fiji ImageJ (https://imagej.net/software/ fiji) and analyzed using Excel (Microsoft).

**Growth and Survival Analyses.** Mice were weighed twice per week in the first 12 wk, once per week up to 40 wk, and once every 2 wk for the remainder of their lifespans. For survival analyses, a combined endpoint of death or distress severe enough that a staff veterinarian blinded to genotype determined that killing was necessary. Killing was performed according to the approved protocol of the Institute of Comparative Medicine at Columbia University Irving Medical Center.

**Blood Biochemical Parameters and Glucose Tolerance Tests.** Mice were fasted for 5 h, and blood was collected and centrifuged at 3,000 x g at 4 °C for 10 min. Plasma was collected and stored at –80 °C until analysis. Blood biochemistry analysis was performed on a Hawksley Element DC Chemistry Analyzer at the Institute of Comparative Medicine, Columbia University Irving Medical Center. Plasma insulin was measured using Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem). For glucose tolerance tests, mice were fasted in clean cages with no food and ad libitum drinking water for 15 h; then blood glucose was measured using One Touch Ultra (LifeScan) at time 0, and then 15, 30, 60, 90, and 120 min after intraperitoneal injection of a 2-g/kg bolus of sterile glucose solution.

For statistical analysis, Student’s t-tests of comparisons between two means were performed using Excel (Microsoft); bar graphs and body mass growth curves were generated using the same software. Statistical significance was set at P < 0.05. The Kaplan–Meier estimator in statistical software GraphPad Prism 5 (Graph Software) was used to generate the survival curves.

**References.**
11. L. G. Fong
Genetically Modifying the Lamin A/C Protein (California, Los Angeles) for antibodies against prelamin A, and the
We thank Drs. Loren Fong and Stephen G. Young (Uni-
with near-normal longevity in mice
Wang et al.
15. C. Kayatekin et al.
18. M. Costanzo et al.
6. J. Barrowman, P. A. Wiley, S. E. Hudson-Miller, C. A. Hrycyna, S. Michaelis, Human
tects against IAPP oligomer-induced proteotoxicity.
3. S. G. Young, M. Meta, S. H. Yang, L. G. Fong, Prelamin A farnesylation and progeroid
9. M. O. Bergo et al.
2. H. J. Worman, S. Michaelis, Permanently farnesylated prelamin A, progeria, and ath-
erosclerosis. Circulation 138, 283–286 (2018).
3. S. G. Young, M. Meta, S. H. Yang, L. G. Fong, Prelamin A farnesylation and progeroid
syndromes. J. Biol. Chem. 281, 39741–39745 (2006).
A. A. De Sandre-Giovanni et al., Lamin a truncation in Hutchinson-Gilford progeria.
Science 300, 2055 (2003).
M. Eriksson et al., Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford
progeria syndrome. Nature 423, 293–298 (2003).
J. Barrowman, P. A. Wiley, S. E. Hudson-Miller, C. A. Hrycyna, S. Michaelis, Human
ZMPSTE24 disease mutations: Residual proteolytic activity correlates with severity.
Hum. Mol. Genet. 21, 4084–4093 (2012).
C. L. Navarro et al., New ZMPSTE24 (FACE1) mutations in patients affected with
restrictive dermopathy or related progeroid syndromes and mutation update. Eur. J.
Hum. Genet. 22, 1020–1024 (2014).
B. C. L. Moulson et al., Homozygous and compound heterozygous mutations in
ZMPSTE24 cause the laminopathy restrictive dermopathy. J. Invest. Dermatol. 125, 913–919 (2005).
M. O. Bergo et al., Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle
weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. U.S.A. 109, 13049–13054 (2002).
A. M. Pendas et al., Defective prelamin A processing and muscular and adipocyte
alterations in Zmpste24 metalloproteinase-deficient mice. Nat. Genet. 31, 94–99 (2002).
L. G. Fong et al., A protein farnesyltransferase inhibitor ameliorates disease in a
mouse model of progeria. Science 313, 1621–1623 (2006).
L. G. Fong et al., Homozygosity for Lmna deficiency eliminates the progeria-like phe-
notypes in Zmpste24-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 101, 18111–18116 (2004).
I. Varela et al., Accelerated ageing in mice deficient in Zmpste24 protease is linked to
p53-signalling activation. Nature 437, 564–568 (2005).
T. Ast, S. Michaels, M. Schuldiner, The protease Ste24 clears clogged translocons.
Cell 164, 103–114 (2016).
C. Kayatekin et al.; AMP T2D-GENES Consortium, Translocon degrader Ste24 prote-
se protects against SAPP oligomer-induced proteotoxicity. Cell 173, 62–73 (2018).
B. Fu, L. Wang, S. Li, M. E. Dorf, ZMPSTE24 defends against influenza and other path-
ogenic viruses. J. Exp. Med. 214, 919–929 (2017).
S. Li, B. Fu, L. Wang, M. E. Dorf, ZMPSTE24 is downstream effector of interferon-
induced transmembrane antiviral activity. DNA Cell Biol. 36, 513–517 (2017).
M. Costanzo et al., The genetic landscape of a cell. Science 327, 425–431 (2010).
A. Hosomi et al., The ER-associated protease Ste24 prevents N-terminal signal
peptide-independent translocation into the endoplasmic reticulum in Saccharomy-
ces cerevisiae. J. Biol. Chem. 295, 10406–10419 (2020).
M. C. Jonikas et al., Comprehensive characterization of genes required for protein
folding in the endoplasmic reticulum. Science 323, 1593–1597 (2009).
A. M. Runnebohm et al., Overlapping function of Hrd1 and Ste24 in translocon qual-
ity control provides robust channel surveillance. J. Biol. Chem. 295, 16113–16120 (2020).
D. J. Tipper, C. A. Harley, Yeast genes controlling responses to topogenic signals in a
model transmembrane protein. Mol. Biol. Cell 13, 1158–1174 (2002).
H. Henneses, E. A. Nigg, The role of isoprenylation in membrane attachment of
nuclear laminas. A single point mutation prevents proteolytic cleavage of the lamin A
precursor and confers membrane binding properties. J. Cell Sci. 107, 1019–1029 (1994).
M. P. Mallampalli, G. Huyer, P. Bendale, M. H. Gelb, S. Michaels, Inhibiting far-
nesylation reverses the nuclear morphology defect in a Hela cell model for
Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. U.S.A. 102, 14416–14421 (2005).
Y. Wang et al., A mutation abolishing the ZMPSTE24 cleavage site in prelamin A
causes a progeroid disorder. J. Cell Sci. 129, 1975–1980 (2016).
W. A. Cabral et al., Genetic reduction of mTOR extends lifespan in a mouse model of
Hutchinson-Gilford progeria syndrome. Aging Cell 20, e13457 (2021).
P. H. Kim et al., Disrupting the LINC complex in smooth muscle cells reduces aortic
disease in a mouse model of Hutchinson-Gilford progeria syndrome. Sci. Transl. Med. 10, eaat7163 (2018).
W. Ma et al., Ste24 induces lamin A splicing as a strategy to treat prelamin A
diseases. J. Clin. Invest. 126, 1592–1602 (2016).
F. G. Osorio et al., Splicing-directed therapy in a new mouse model of human inher-
ited aging. Sci. Transl. Med. 3, 106ra107 (2011).
58. Y. Liu, I. Drozdov, R. Shroff, L. E. Beltran, C. M. Shanahan, Prelamin A accelerates vascular calcification via activation of the DNA damage response and senescence-associated secretory phenotype in vascular smooth muscle cells. *Circ. Res.* **112**, e99–e109 (2013).

59. S. Warming, N. Costantino, D. L. Court, N. A. Jenkins, N. G. Copeland, Simple and highly efficient BAC recombineering using galK selection. *Nucleic Acids Res.* **33**, e36 (2005).

60. Y. Wang et al., Postnatal development of mice with combined genetic depletions of lamin A/C, emerin and lamina-associated polypeptide 1. *Hum. Mol. Genet.* **28**, 2486–2500 (2019).

61. Y. Tu, S. Sánchez-Iglesias, D. Araújo-Vilar, L. G. Fong, S. G. Young, LMNA missense mutations causing familial partial lipodystrophy do not lead to an accumulation of prelamin A. *Nucleus* **7**, 512–521 (2016).

62. A. Aartsma-Rus, M. van Putten, Assessing functional performance in the mdx mouse model. *J. Vis. Exp.* **85**, 51303 (2014).

63. M. E. Durkin, X. Qian, N. C. Popescu, D. R. Lowy, Isolation of mouse embryo fibroblasts. *Bio Protoc.* **3**, e988 (2013).

64. T. D. Babatz et al., Site specificity determinants for prelamin A cleavage by the zinc metalloprotease ZMPSTE24. *J. Biol. Chem.* **296**, 100165 (2021).